Addus HomeCare Corp (NASDAQ:ADUS) recently saw insider activity as Executive Vice President and Chief Development Officer Cliff Donald Blessing sold 178 shares of the company's common stock. The transaction, finalized on April 21, 2026, was conducted at a price of $93.61 per share, bringing the total value of the sale to $16,662.
This specific trade was carried out under the framework of a 10b5-1 trading plan, which was originally adopted on March 14, 2025. The liquidation was intended to cover tax obligations triggered by the vesting of restricted stock awards provided by Addus HomeCare. After completing this transaction, Mr. Blessing's direct ownership in the company stands at 12,183 shares.
Market Context and Valuation
The timing of this sale coincides with a period of price sensitivity for ADUS. The stock is currently trading at $94.77, which places it near its 52-week low of $90.89. Despite the recent downward pressure on the share price, certain valuation metrics suggest potential undervaluation. Analysis indicates that the company is trading at a Price-to-Earnings (P/E) ratio of 18.04 and a PEG ratio of 0.74.
Analyst Perspectives and Segment Performance
Recent fourth-quarter financial results for Addus HomeCare have led to a variety of outlooks from major investment firms, reflecting both operational strengths and specific headwinds in the healthcare services sector:
- Truist Securities has reiterated a Buy rating for the company, pointing toward margin improvements and robust growth within the Hospice and Personal Care segments.
- RBC Capital maintained an Outperform rating, citing positive rate momentum and the sustained high demand for personal care services.
- KeyBanc also issued a reiteration of its Overweight rating, noting that the company achieved a 3% EBITDA beat, which was fueled by strong revenue growth in the same-store Personal Care business.
- Citizens kept a Market Outperform rating with a price target of $150, leaving its projections for 2026-2027 EBITDA unchanged.
- Stephens provided a more cautious view, lowering its price target from $140 to $135. This adjustment was attributed to a 1.1% year-over-year decline in the segment billable census, even though same-store hours rose by 2.4%.
Overall, the consensus among analysts presents a mixed but generally positive trajectory for Addus HomeCare, with much of the focus remaining on the company's ability to manage growth across its core service lines.